VTYX News and Press, Ventyx Biosciences Inc. From 09/23/22

Summary Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu. As suc...

Ventyx Biosciences| ( NASDAQ: VTYX ) has entered into a stock purchase agreement for the sale of 5.35M shares of its common stock at an offering price of $33.00/share in a private placement to certain qualified institutional buyers and institutional accredited investors. T...

ENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, ann...

Summary Today, we take our first look at Ventyx Biosciences, Inc., a small California based biotech firm with a promising pipeline. A FDA approval triggered a big rally in this heavily shorted stock this week.  However, is the rise sustainable? An investment analysis foll...

One standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX) . According to data compiled by S&P Global Market Intelligence , the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that has...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Illus_man / Shutterstock AST SpaceMobile (NASDAQ: ASTS ) stock is in the news Monday as the company’s BlueWalker 3 satellite enters Earth’s orbit . BlueWalker 3 is a test satellite that ...

Ventyx Biosciences ( NASDAQ: VTYX ) stock soared ~69% on Sept. 12 after Bristol-Myers Squibb's ( BMY ) TYK2 inhibitor Sotyktu (deucravacitinib) for plaque psoriasis was approved in the U.S. without a black-box warning. H.C. Wainwright Analyst Emily Bodnar no...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: metamorworks / Shutterstock Ventyx Biosciences (NASDAQ: VTYX ) stock is rocketing higher on Monday after Oppenheimer analyst Jeff Jones provided an update on the shares . That update has the Oppenheim...

Dan Loeb's 13F portfolio value decreased from $7.68B to $4.22B this quarter. The number of positions decreased from 75 to 58. Third Point added Colgate-Palmolive, Antero Resources, Walt Disney, and T-Mobile US. They also increased Ovintiv. However, net equity exposure was cut sharply ...

Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...